 Alexis Leal
Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 1579 | 1.020 |
Why?
| | Myeloproliferative Disorders | 2 | 2015 | 26 | 0.930 |
Why?
| | Antiemetics | 4 | 2018 | 40 | 0.790 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2023 | 72 | 0.780 |
Why?
| | Immunoconjugates | 2 | 2023 | 101 | 0.750 |
Why?
| | Colorectal Neoplasms | 5 | 2024 | 733 | 0.570 |
Why?
| | Phlebitis | 2 | 2014 | 11 | 0.560 |
Why?
| | Morpholines | 2 | 2014 | 126 | 0.530 |
Why?
| | Reproductive History | 1 | 2015 | 18 | 0.500 |
Why?
| | Paclitaxel | 4 | 2024 | 216 | 0.500 |
Why?
| | Hematologic Neoplasms | 1 | 2017 | 142 | 0.490 |
Why?
| | Antineoplastic Agents | 5 | 2023 | 2078 | 0.490 |
Why?
| | Hormone Replacement Therapy | 1 | 2015 | 91 | 0.470 |
Why?
| | Breast Neoplasms | 2 | 2017 | 2139 | 0.430 |
Why?
| | Postmenopause | 1 | 2015 | 370 | 0.420 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2014 | 126 | 0.410 |
Why?
| | Cancer Survivors | 1 | 2017 | 263 | 0.410 |
Why?
| | Physician-Patient Relations | 1 | 2017 | 541 | 0.400 |
Why?
| | Glutathione | 1 | 2014 | 340 | 0.390 |
Why?
| | Nausea | 4 | 2018 | 109 | 0.380 |
Why?
| | Vomiting | 4 | 2018 | 129 | 0.370 |
Why?
| | Pancreatic Neoplasms | 3 | 2024 | 892 | 0.370 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2024 | 269 | 0.360 |
Why?
| | Decision Making | 1 | 2017 | 842 | 0.340 |
Why?
| | Aged, 80 and over | 10 | 2024 | 7128 | 0.330 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2785 | 0.320 |
Why?
| | Physicians | 1 | 2017 | 865 | 0.310 |
Why?
| | Neoplasms | 4 | 2023 | 2467 | 0.300 |
Why?
| | Cyclophosphamide | 3 | 2017 | 232 | 0.270 |
Why?
| | Aged | 15 | 2024 | 22282 | 0.270 |
Why?
| | Doxorubicin | 3 | 2017 | 321 | 0.250 |
Why?
| | Middle Aged | 16 | 2024 | 31322 | 0.240 |
Why?
| | Isoquinolines | 1 | 2024 | 42 | 0.230 |
Why?
| | Albumins | 1 | 2024 | 103 | 0.220 |
Why?
| | Bevacizumab | 1 | 2024 | 132 | 0.220 |
Why?
| | Benzimidazoles | 1 | 2024 | 160 | 0.210 |
Why?
| | Oncogene Proteins, Viral | 1 | 2023 | 22 | 0.210 |
Why?
| | Survival Rate | 4 | 2021 | 1904 | 0.190 |
Why?
| | Fluorouracil | 1 | 2022 | 201 | 0.190 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2024 | 763 | 0.190 |
Why?
| | Pyrazoles | 1 | 2024 | 406 | 0.180 |
Why?
| | Conscious Sedation | 2 | 2013 | 85 | 0.180 |
Why?
| | Pyridines | 1 | 2024 | 474 | 0.180 |
Why?
| | Antigens, Neoplasm | 2 | 2024 | 311 | 0.170 |
Why?
| | Prognosis | 3 | 2020 | 3830 | 0.170 |
Why?
| | DNA Mismatch Repair | 1 | 2020 | 47 | 0.170 |
Why?
| | Female | 16 | 2024 | 68842 | 0.160 |
Why?
| | Humans | 23 | 2024 | 130305 | 0.160 |
Why?
| | Papillomavirus Infections | 1 | 2023 | 291 | 0.160 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2024 | 755 | 0.160 |
Why?
| | Patient Compliance | 2 | 2021 | 565 | 0.160 |
Why?
| | Adult | 12 | 2024 | 35711 | 0.160 |
Why?
| | Vaccines | 1 | 2024 | 404 | 0.150 |
Why?
| | Drug Design | 1 | 2018 | 157 | 0.140 |
Why?
| | Office Visits | 1 | 2017 | 85 | 0.140 |
Why?
| | Insurance Claim Review | 1 | 2017 | 75 | 0.140 |
Why?
| | Follow-Up Studies | 2 | 2017 | 4961 | 0.140 |
Why?
| | Eligibility Determination | 1 | 2017 | 64 | 0.140 |
Why?
| | Codon | 1 | 2017 | 88 | 0.140 |
Why?
| | Mastectomy | 1 | 2017 | 130 | 0.130 |
Why?
| | Lymph Node Excision | 1 | 2017 | 168 | 0.130 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 383 | 0.130 |
Why?
| | Infusions, Intravenous | 2 | 2014 | 395 | 0.130 |
Why?
| | Drug Prescriptions | 1 | 2018 | 255 | 0.120 |
Why?
| | Immunotherapy | 1 | 2020 | 599 | 0.120 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2017 | 214 | 0.120 |
Why?
| | Iowa | 1 | 2013 | 28 | 0.110 |
Why?
| | Prospective Studies | 3 | 2015 | 7131 | 0.110 |
Why?
| | Carboplatin | 1 | 2014 | 140 | 0.110 |
Why?
| | Placebos | 1 | 2014 | 204 | 0.110 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2014 | 78 | 0.110 |
Why?
| | Complementary Therapies | 1 | 2014 | 87 | 0.110 |
Why?
| | Medical Order Entry Systems | 1 | 2013 | 44 | 0.100 |
Why?
| | Anthropometry | 1 | 2013 | 206 | 0.100 |
Why?
| | Hip Prosthesis | 1 | 2013 | 34 | 0.100 |
Why?
| | Hip Dislocation | 1 | 2013 | 48 | 0.100 |
Why?
| | Prosthesis Failure | 1 | 2013 | 124 | 0.100 |
Why?
| | Male | 12 | 2024 | 63748 | 0.100 |
Why?
| | Neoplasm Staging | 1 | 2015 | 1294 | 0.100 |
Why?
| | Antibodies, Monoclonal | 1 | 2018 | 1372 | 0.100 |
Why?
| | Risk Factors | 3 | 2015 | 9865 | 0.100 |
Why?
| | Retrospective Studies | 7 | 2021 | 14675 | 0.090 |
Why?
| | Life Style | 1 | 2013 | 461 | 0.090 |
Why?
| | Survivors | 1 | 2014 | 463 | 0.090 |
Why?
| | Women's Health | 1 | 2013 | 362 | 0.090 |
Why?
| | Analgesia | 1 | 2010 | 94 | 0.080 |
Why?
| | Young Adult | 5 | 2018 | 12404 | 0.080 |
Why?
| | Double-Blind Method | 1 | 2014 | 1878 | 0.080 |
Why?
| | Guideline Adherence | 1 | 2013 | 534 | 0.080 |
Why?
| | Neoplasm Metastasis | 2 | 2024 | 615 | 0.080 |
Why?
| | Motor Activity | 1 | 2013 | 670 | 0.080 |
Why?
| | Case-Control Studies | 1 | 2015 | 3369 | 0.070 |
Why?
| | Health Status | 1 | 2013 | 756 | 0.070 |
Why?
| | Cohort Studies | 1 | 2017 | 5431 | 0.070 |
Why?
| | Age Factors | 3 | 2021 | 3153 | 0.060 |
Why?
| | Smoking | 1 | 2013 | 1505 | 0.060 |
Why?
| | Mutation | 1 | 2017 | 3723 | 0.060 |
Why?
| | Cell Line, Tumor | 2 | 2024 | 3185 | 0.060 |
Why?
| | Body Mass Index | 1 | 2013 | 2268 | 0.060 |
Why?
| | Microsatellite Repeats | 1 | 2024 | 164 | 0.050 |
Why?
| | Papillomavirus E7 Proteins | 1 | 2023 | 10 | 0.050 |
Why?
| | Receptors, Enterotoxin | 1 | 2023 | 4 | 0.050 |
Why?
| | Emergency Service, Hospital | 2 | 2013 | 1986 | 0.050 |
Why?
| | HLA-A Antigens | 1 | 2023 | 53 | 0.050 |
Why?
| | Organoids | 1 | 2024 | 104 | 0.050 |
Why?
| | Deoxycytidine | 1 | 2024 | 167 | 0.050 |
Why?
| | Human papillomavirus 16 | 1 | 2023 | 33 | 0.050 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 46 | 0.050 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 65 | 0.050 |
Why?
| | Maximum Tolerated Dose | 1 | 2023 | 196 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 265 | 0.050 |
Why?
| | Wnt Signaling Pathway | 1 | 2024 | 169 | 0.050 |
Why?
| | Mice, Nude | 1 | 2024 | 688 | 0.050 |
Why?
| | Camptothecin | 1 | 2022 | 107 | 0.050 |
Why?
| | Surveys and Questionnaires | 1 | 2014 | 5400 | 0.050 |
Why?
| | Adolescent | 2 | 2018 | 20374 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2013 | 2511 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2024 | 815 | 0.050 |
Why?
| | United Kingdom | 2 | 2013 | 266 | 0.050 |
Why?
| | Animals | 2 | 2024 | 35076 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2023 | 372 | 0.040 |
Why?
| | Antibodies | 1 | 2023 | 398 | 0.040 |
Why?
| | Obesity | 1 | 2013 | 2869 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 550 | 0.040 |
Why?
| | Ipilimumab | 1 | 2020 | 29 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2020 | 37 | 0.040 |
Why?
| | Sex Factors | 2 | 2017 | 1965 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2021 | 387 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2024 | 10341 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2023 | 1983 | 0.040 |
Why?
| | Peptides | 1 | 2024 | 917 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2020 | 186 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2024 | 959 | 0.040 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 227 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2018 | 68 | 0.040 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1196 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2020 | 313 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2024 | 2381 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2017 | 282 | 0.030 |
Why?
| | Patient Selection | 1 | 2020 | 678 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1015 | 0.030 |
Why?
| | Anthracyclines | 1 | 2014 | 46 | 0.030 |
Why?
| | Apoptosis | 1 | 2022 | 2519 | 0.030 |
Why?
| | United States | 2 | 2021 | 14110 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2010 | 112 | 0.020 |
Why?
| | Hospitals, Urban | 1 | 2010 | 134 | 0.020 |
Why?
| | Logistic Models | 1 | 2013 | 1980 | 0.020 |
Why?
| | Mice | 1 | 2024 | 16832 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2010 | 1510 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2013 | 979 | 0.020 |
Why?
|
|
Leal's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|